• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer
Conclusions Cancer history is linked to increased risk of incident CVDs and adverse cardiac remodelling independent of shared vascular risk factors.
Source: Heart - June 14, 2023 Category: Cardiology Authors: Raisi-Estabragh, Z., Cooper, J., McCracken, C., Crosbie, E. J., Walter, F. M., Manisty, C. H., Robson, J., Mamas, M. A., Harvey, N. C., Neubauer, S., Petersen, S. E. Tags: Open access, Editor's choice, Press releases Cardiac risk factors and prevention Source Type: research

The Intersection of Prostate Cancer and Hypertension: a Call to Action
Opinion statementWith improvements in treatment and survival from prostate cancer, comorbid cardiac conditions will significantly impact overall morbidity and mortality from prostate cancer. Hypertension is a well-established cardiovascular risk factor that increases the risk of heart failure, myocardial infarction, and stroke. Therapies used in the treatment of prostate cancer, including GnRH agonists, GnRH antagonists, enzalutamide, abiraterone, and others, can directly or indirectly increase the risk of hypertension. In this paper, we review the evidence available on the incidence and mechanism of hypertension in prosta...
Source: Current Treatment Options in Oncology - May 16, 2023 Category: Cancer & Oncology Source Type: research

ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis
ConclusionGnRH antagonists appear to offer favorable safety in terms of adverse CV events and CV death compared with GnRH agonists among men diagnosed with Pca, especially those who had established CV disease at baseline.Systematic review registrationhttps://inplasy.com/inplasy-2023-2-0009/, identifier INPLASY202320009.
Source: Frontiers in Endocrinology - March 31, 2023 Category: Endocrinology Source Type: research

Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data
CONCLUSION: Concordance between datasets was lower than anticipated and the HSD used could not straightforwardly replace current trial practices, nor directly identify protocol-defined CVS events. Further work is required to improve the quality of HSD and consider event definitions when designing clinical trials incorporating HSD.PMID:36933612 | DOI:10.1016/j.cct.2023.107162
Source: Clinical Prostate Cancer - March 18, 2023 Category: Cancer & Oncology Authors: Archie Macnair Matthew Nankivell Macey L Murray Stuart D Rosen Sally Appleyard Matthew R Sydes Sylvia Forcat Andrew Welland Noel W Clarke Stephen Mangar Howard Kynaston Roger Kockelbergh Abdulla Al-Hasso John Deighan John Marshall Mahesh Parmar Ruth E Lan Source Type: research

Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data
CONCLUSIONS: Our study sought to quantify risk of HHF, AMI and ischemic stroke among CRPC patients initiating AAP relative to ENZ within a national administrative claims database. Increased risk for HHF among AAP compared to ENZ users was observed. The difference in myocardial infarction did not attain statistical significance after controlling for residual bias, and no differences were noted in ischemic stroke between the two treatments. These findings confirm labeled warnings and precautions for AAP for HHF and contribute to the comparative real-world evidence on AAP relative to ENZ.PMID:36879362 | DOI:10.1002/pros.24510
Source: Cancer Control - March 6, 2023 Category: Cancer & Oncology Authors: Mitchell M Conover James Weaver Bo Fan Gerhard Leitz Ute Richarz Qing Li Dina Gifkins Source Type: research

Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk
CONCLUSIONS: Compared with GnRH agonists, the GnRH antagonist was found to be associated with a decreased risk of HF, specifically among patients with prior CVD. Among those with no prior CVD, the GnRH antagonist was associated with a decreased risk of IHD but an increased risk of arrhythmia.PMID:36791755 | DOI:10.6004/jnccn.2022.7083
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 15, 2023 Category: Cancer & Oncology Authors: Alice Dragomir Nawar Touma Jason Hu Sylvie Perreault Armen G Aprikian Source Type: research

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Impact of cancer diagnosis on distribution and trends of cardiovascular hospitalizations in the USA between 2004 to 2017
CONCLUSIONS: In contrast to declining trends in patients without cancer, primary cardiovascular admissions in patients with cancer is increasing. The highest admission rates are in patients with hematological cancer and the most common cause of admission is heart failure.PMID:35913736 | DOI:10.1093/ehjqcco/qcac045
Source: Clinical Lung Cancer - August 1, 2022 Category: Cancer & Oncology Authors: Ofer Kobo Zahra Raisi-Estabragh Sofie Gevaert Jamal S Rana Harriette G C Van Spall Ariel Roguin Steffen E Petersen Bonnie Ky Mamas A Mamas Source Type: research

Pages: 1  2  3